J HEPATOL:HBsAg水平和白介素-28B基因型可预测尿毒症患者HCV的自发清除率

2013-10-09 佚名 丁香园

宿主因素和病毒因素二者相互作用,共同影响丙型肝炎病毒(HCV)感染的自发清除率。来自台湾高雄医学大学附属医院内科部门的余明隆教授及其同事就此展开一项研究,研究结果在线发表于2013年10月3日的《肝脏病学杂志》(Journal of Hepatology)杂志上。作者发现,HBsAg水平较高且携带白介素-28B有利基因型的尿毒症患者HCV自发清除率也较高。【原文下载】 本研究旨在探索白介素-28

宿主因素和病毒因素二者相互作用,共同影响丙型肝炎病毒(HCV)感染的自发清除率。来自台湾高雄医学大学附属医院内科部门的余明隆教授及其同事就此展开一项研究,研究结果在线发表于2013年10月3日的《肝脏病学杂志》(Journal of Hepatology)杂志上。作者发现,HBsAg水平较高且携带白介素-28B有利基因型的尿毒症患者HCV自发清除率也较高。【原文下载

本研究旨在探索白介素-28B基因型和乙型肝炎病毒(HBV)感染对尿毒症HCV自发清除率的影响。在总共1681例依靠维持性血液透析的尿毒症患者中,对其中290例HCV抗体血清反应阳性患者的白介素-28B rs8099917基因型、HCV和HBV标志物进行检测。

研究结果如下:在287例患者中的74.6%观察到持续性HCV病毒血症。逻辑回归分析表明,与HCV自发清除率相关性最强的因素是携带rs8099917 TT基因型,其次是并发乙型肝炎表面抗原(HBsAg)血清反应阳性。相比于HBsAg阴性且携带rs8099917 非TT基因型的患者,HBsAg阳性且携带rs8099917 TT基因型患者的HCV自发清除率最高,HBsAg阳性且携带rs8099917 非TT基因型患者次之,随后是HBsAg阴性且携带rs8099917 TT基因型的患者。

HBsAg水平,而非HBV DNA水平,与HCV的自发清除率显著相关。HBsAg水平高于200 IU/mL且携带rs8099917 TT基因型患者的HCV自发清除率为58.3%,HBsAg水平低于200 IU/mL且携带rs8099917 TT基因型患者或HBsAg水平高于200 IU/mL且携带rs8099917非TT基因型患者为28.0%,相比之下,HBsAg水平低于200 IU/mL且携带rs8099917非TT基因型患者仅为3.3%.在登记之初罹患HCV病毒血症的214例患者中,有5例在一年随访期内即实现HCV的自发清除,这一自发清除的实现与基线HCV RNA水平和HBsAg水平相关。

研究发现,高HBsAg水平及携带白介素-28B有利基因型与尿毒症患者HCV的自发清除率呈叠加性相关关系。可根据HbsAg水平及白介素-28B基因型预测尿毒症患者HCV的自发清除率。HBsAg水平较高且携带白介素-28B有利基因型的尿毒症患者HCV自发清除率也较高。

原文检索

Yu ML, Dai CY, Huang CF, Lee JJ, Yeh ML, Yeh SM, Kuo HT, Huang JF, Chang JM, Chen HC, Juo SH, Hwang SJ, Chuang WL; the FORMOSA-LIKE group.High hepatitis B virus surface antigen levels and favorable interleukin 28B genotype predict spontaneous hepatitis C virus clearance in uremic patients.J Hepatol. 2013 Oct 1.【原文下载

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1953252, encodeId=c30b1953252ab, content=<a href='/topic/show?id=500be1632c1' target=_blank style='color:#2F92EE;'>#白介素-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71632, encryptionId=500be1632c1, topicName=白介素-2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Sat May 24 05:15:00 CST 2014, time=2014-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890796, encodeId=8d781890e9650, content=<a href='/topic/show?id=742341e1782' target=_blank style='color:#2F92EE;'>#基因型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41717, encryptionId=742341e1782, topicName=基因型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Wed Jun 04 03:15:00 CST 2014, time=2014-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1670527, encodeId=53e016e05277d, content=<a href='/topic/show?id=7bc54e43473' target=_blank style='color:#2F92EE;'>#尿毒症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47434, encryptionId=7bc54e43473, topicName=尿毒症患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b24f26728715, createdName=chenwq17, createdTime=Sun Jan 19 08:15:00 CST 2014, time=2014-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257571, encodeId=15d3125e57123, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Fri Oct 11 07:15:00 CST 2013, time=2013-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290387, encodeId=88e6129038e13, content=<a href='/topic/show?id=facb4e432e4' target=_blank style='color:#2F92EE;'>#尿毒症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47432, encryptionId=facb4e432e4, topicName=尿毒症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74c2229, createdName=tcm99hq, createdTime=Fri Oct 11 07:15:00 CST 2013, time=2013-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338656, encodeId=f6f11338656bf, content=<a href='/topic/show?id=e803851e58' target=_blank style='color:#2F92EE;'>#HBsAg#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8517, encryptionId=e803851e58, topicName=HBsAg)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a5c2500147, createdName=12498bb3m90(暂无昵称), createdTime=Fri Oct 11 07:15:00 CST 2013, time=2013-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372095, encodeId=1e2213e2095f5, content=<a href='/topic/show?id=6ca1e1621c4' target=_blank style='color:#2F92EE;'>#白介素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71621, encryptionId=6ca1e1621c4, topicName=白介素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e95336, createdName=budeshao, createdTime=Fri Oct 11 07:15:00 CST 2013, time=2013-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426558, encodeId=390c142655881, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Fri Oct 11 07:15:00 CST 2013, time=2013-10-11, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1953252, encodeId=c30b1953252ab, content=<a href='/topic/show?id=500be1632c1' target=_blank style='color:#2F92EE;'>#白介素-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71632, encryptionId=500be1632c1, topicName=白介素-2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Sat May 24 05:15:00 CST 2014, time=2014-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890796, encodeId=8d781890e9650, content=<a href='/topic/show?id=742341e1782' target=_blank style='color:#2F92EE;'>#基因型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41717, encryptionId=742341e1782, topicName=基因型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Wed Jun 04 03:15:00 CST 2014, time=2014-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1670527, encodeId=53e016e05277d, content=<a href='/topic/show?id=7bc54e43473' target=_blank style='color:#2F92EE;'>#尿毒症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47434, encryptionId=7bc54e43473, topicName=尿毒症患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b24f26728715, createdName=chenwq17, createdTime=Sun Jan 19 08:15:00 CST 2014, time=2014-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257571, encodeId=15d3125e57123, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Fri Oct 11 07:15:00 CST 2013, time=2013-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290387, encodeId=88e6129038e13, content=<a href='/topic/show?id=facb4e432e4' target=_blank style='color:#2F92EE;'>#尿毒症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47432, encryptionId=facb4e432e4, topicName=尿毒症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74c2229, createdName=tcm99hq, createdTime=Fri Oct 11 07:15:00 CST 2013, time=2013-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338656, encodeId=f6f11338656bf, content=<a href='/topic/show?id=e803851e58' target=_blank style='color:#2F92EE;'>#HBsAg#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8517, encryptionId=e803851e58, topicName=HBsAg)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a5c2500147, createdName=12498bb3m90(暂无昵称), createdTime=Fri Oct 11 07:15:00 CST 2013, time=2013-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372095, encodeId=1e2213e2095f5, content=<a href='/topic/show?id=6ca1e1621c4' target=_blank style='color:#2F92EE;'>#白介素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71621, encryptionId=6ca1e1621c4, topicName=白介素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e95336, createdName=budeshao, createdTime=Fri Oct 11 07:15:00 CST 2013, time=2013-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426558, encodeId=390c142655881, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Fri Oct 11 07:15:00 CST 2013, time=2013-10-11, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1953252, encodeId=c30b1953252ab, content=<a href='/topic/show?id=500be1632c1' target=_blank style='color:#2F92EE;'>#白介素-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71632, encryptionId=500be1632c1, topicName=白介素-2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Sat May 24 05:15:00 CST 2014, time=2014-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890796, encodeId=8d781890e9650, content=<a href='/topic/show?id=742341e1782' target=_blank style='color:#2F92EE;'>#基因型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41717, encryptionId=742341e1782, topicName=基因型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Wed Jun 04 03:15:00 CST 2014, time=2014-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1670527, encodeId=53e016e05277d, content=<a href='/topic/show?id=7bc54e43473' target=_blank style='color:#2F92EE;'>#尿毒症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47434, encryptionId=7bc54e43473, topicName=尿毒症患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b24f26728715, createdName=chenwq17, createdTime=Sun Jan 19 08:15:00 CST 2014, time=2014-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257571, encodeId=15d3125e57123, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Fri Oct 11 07:15:00 CST 2013, time=2013-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290387, encodeId=88e6129038e13, content=<a href='/topic/show?id=facb4e432e4' target=_blank style='color:#2F92EE;'>#尿毒症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47432, encryptionId=facb4e432e4, topicName=尿毒症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74c2229, createdName=tcm99hq, createdTime=Fri Oct 11 07:15:00 CST 2013, time=2013-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338656, encodeId=f6f11338656bf, content=<a href='/topic/show?id=e803851e58' target=_blank style='color:#2F92EE;'>#HBsAg#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8517, encryptionId=e803851e58, topicName=HBsAg)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a5c2500147, createdName=12498bb3m90(暂无昵称), createdTime=Fri Oct 11 07:15:00 CST 2013, time=2013-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372095, encodeId=1e2213e2095f5, content=<a href='/topic/show?id=6ca1e1621c4' target=_blank style='color:#2F92EE;'>#白介素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71621, encryptionId=6ca1e1621c4, topicName=白介素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e95336, createdName=budeshao, createdTime=Fri Oct 11 07:15:00 CST 2013, time=2013-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426558, encodeId=390c142655881, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Fri Oct 11 07:15:00 CST 2013, time=2013-10-11, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1953252, encodeId=c30b1953252ab, content=<a href='/topic/show?id=500be1632c1' target=_blank style='color:#2F92EE;'>#白介素-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71632, encryptionId=500be1632c1, topicName=白介素-2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Sat May 24 05:15:00 CST 2014, time=2014-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890796, encodeId=8d781890e9650, content=<a href='/topic/show?id=742341e1782' target=_blank style='color:#2F92EE;'>#基因型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41717, encryptionId=742341e1782, topicName=基因型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Wed Jun 04 03:15:00 CST 2014, time=2014-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1670527, encodeId=53e016e05277d, content=<a href='/topic/show?id=7bc54e43473' target=_blank style='color:#2F92EE;'>#尿毒症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47434, encryptionId=7bc54e43473, topicName=尿毒症患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b24f26728715, createdName=chenwq17, createdTime=Sun Jan 19 08:15:00 CST 2014, time=2014-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257571, encodeId=15d3125e57123, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Fri Oct 11 07:15:00 CST 2013, time=2013-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290387, encodeId=88e6129038e13, content=<a href='/topic/show?id=facb4e432e4' target=_blank style='color:#2F92EE;'>#尿毒症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47432, encryptionId=facb4e432e4, topicName=尿毒症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74c2229, createdName=tcm99hq, createdTime=Fri Oct 11 07:15:00 CST 2013, time=2013-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338656, encodeId=f6f11338656bf, content=<a href='/topic/show?id=e803851e58' target=_blank style='color:#2F92EE;'>#HBsAg#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8517, encryptionId=e803851e58, topicName=HBsAg)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a5c2500147, createdName=12498bb3m90(暂无昵称), createdTime=Fri Oct 11 07:15:00 CST 2013, time=2013-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372095, encodeId=1e2213e2095f5, content=<a href='/topic/show?id=6ca1e1621c4' target=_blank style='color:#2F92EE;'>#白介素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71621, encryptionId=6ca1e1621c4, topicName=白介素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e95336, createdName=budeshao, createdTime=Fri Oct 11 07:15:00 CST 2013, time=2013-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426558, encodeId=390c142655881, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Fri Oct 11 07:15:00 CST 2013, time=2013-10-11, status=1, ipAttribution=)]
    2013-10-11 ymljack
  5. [GetPortalCommentsPageByObjectIdResponse(id=1953252, encodeId=c30b1953252ab, content=<a href='/topic/show?id=500be1632c1' target=_blank style='color:#2F92EE;'>#白介素-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71632, encryptionId=500be1632c1, topicName=白介素-2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Sat May 24 05:15:00 CST 2014, time=2014-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890796, encodeId=8d781890e9650, content=<a href='/topic/show?id=742341e1782' target=_blank style='color:#2F92EE;'>#基因型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41717, encryptionId=742341e1782, topicName=基因型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Wed Jun 04 03:15:00 CST 2014, time=2014-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1670527, encodeId=53e016e05277d, content=<a href='/topic/show?id=7bc54e43473' target=_blank style='color:#2F92EE;'>#尿毒症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47434, encryptionId=7bc54e43473, topicName=尿毒症患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b24f26728715, createdName=chenwq17, createdTime=Sun Jan 19 08:15:00 CST 2014, time=2014-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257571, encodeId=15d3125e57123, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Fri Oct 11 07:15:00 CST 2013, time=2013-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290387, encodeId=88e6129038e13, content=<a href='/topic/show?id=facb4e432e4' target=_blank style='color:#2F92EE;'>#尿毒症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47432, encryptionId=facb4e432e4, topicName=尿毒症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74c2229, createdName=tcm99hq, createdTime=Fri Oct 11 07:15:00 CST 2013, time=2013-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338656, encodeId=f6f11338656bf, content=<a href='/topic/show?id=e803851e58' target=_blank style='color:#2F92EE;'>#HBsAg#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8517, encryptionId=e803851e58, topicName=HBsAg)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a5c2500147, createdName=12498bb3m90(暂无昵称), createdTime=Fri Oct 11 07:15:00 CST 2013, time=2013-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372095, encodeId=1e2213e2095f5, content=<a href='/topic/show?id=6ca1e1621c4' target=_blank style='color:#2F92EE;'>#白介素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71621, encryptionId=6ca1e1621c4, topicName=白介素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e95336, createdName=budeshao, createdTime=Fri Oct 11 07:15:00 CST 2013, time=2013-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426558, encodeId=390c142655881, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Fri Oct 11 07:15:00 CST 2013, time=2013-10-11, status=1, ipAttribution=)]
    2013-10-11 tcm99hq
  6. [GetPortalCommentsPageByObjectIdResponse(id=1953252, encodeId=c30b1953252ab, content=<a href='/topic/show?id=500be1632c1' target=_blank style='color:#2F92EE;'>#白介素-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71632, encryptionId=500be1632c1, topicName=白介素-2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Sat May 24 05:15:00 CST 2014, time=2014-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890796, encodeId=8d781890e9650, content=<a href='/topic/show?id=742341e1782' target=_blank style='color:#2F92EE;'>#基因型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41717, encryptionId=742341e1782, topicName=基因型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Wed Jun 04 03:15:00 CST 2014, time=2014-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1670527, encodeId=53e016e05277d, content=<a href='/topic/show?id=7bc54e43473' target=_blank style='color:#2F92EE;'>#尿毒症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47434, encryptionId=7bc54e43473, topicName=尿毒症患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b24f26728715, createdName=chenwq17, createdTime=Sun Jan 19 08:15:00 CST 2014, time=2014-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257571, encodeId=15d3125e57123, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Fri Oct 11 07:15:00 CST 2013, time=2013-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290387, encodeId=88e6129038e13, content=<a href='/topic/show?id=facb4e432e4' target=_blank style='color:#2F92EE;'>#尿毒症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47432, encryptionId=facb4e432e4, topicName=尿毒症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74c2229, createdName=tcm99hq, createdTime=Fri Oct 11 07:15:00 CST 2013, time=2013-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338656, encodeId=f6f11338656bf, content=<a href='/topic/show?id=e803851e58' target=_blank style='color:#2F92EE;'>#HBsAg#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8517, encryptionId=e803851e58, topicName=HBsAg)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a5c2500147, createdName=12498bb3m90(暂无昵称), createdTime=Fri Oct 11 07:15:00 CST 2013, time=2013-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372095, encodeId=1e2213e2095f5, content=<a href='/topic/show?id=6ca1e1621c4' target=_blank style='color:#2F92EE;'>#白介素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71621, encryptionId=6ca1e1621c4, topicName=白介素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e95336, createdName=budeshao, createdTime=Fri Oct 11 07:15:00 CST 2013, time=2013-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426558, encodeId=390c142655881, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Fri Oct 11 07:15:00 CST 2013, time=2013-10-11, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1953252, encodeId=c30b1953252ab, content=<a href='/topic/show?id=500be1632c1' target=_blank style='color:#2F92EE;'>#白介素-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71632, encryptionId=500be1632c1, topicName=白介素-2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Sat May 24 05:15:00 CST 2014, time=2014-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890796, encodeId=8d781890e9650, content=<a href='/topic/show?id=742341e1782' target=_blank style='color:#2F92EE;'>#基因型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41717, encryptionId=742341e1782, topicName=基因型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Wed Jun 04 03:15:00 CST 2014, time=2014-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1670527, encodeId=53e016e05277d, content=<a href='/topic/show?id=7bc54e43473' target=_blank style='color:#2F92EE;'>#尿毒症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47434, encryptionId=7bc54e43473, topicName=尿毒症患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b24f26728715, createdName=chenwq17, createdTime=Sun Jan 19 08:15:00 CST 2014, time=2014-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257571, encodeId=15d3125e57123, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Fri Oct 11 07:15:00 CST 2013, time=2013-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290387, encodeId=88e6129038e13, content=<a href='/topic/show?id=facb4e432e4' target=_blank style='color:#2F92EE;'>#尿毒症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47432, encryptionId=facb4e432e4, topicName=尿毒症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74c2229, createdName=tcm99hq, createdTime=Fri Oct 11 07:15:00 CST 2013, time=2013-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338656, encodeId=f6f11338656bf, content=<a href='/topic/show?id=e803851e58' target=_blank style='color:#2F92EE;'>#HBsAg#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8517, encryptionId=e803851e58, topicName=HBsAg)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a5c2500147, createdName=12498bb3m90(暂无昵称), createdTime=Fri Oct 11 07:15:00 CST 2013, time=2013-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372095, encodeId=1e2213e2095f5, content=<a href='/topic/show?id=6ca1e1621c4' target=_blank style='color:#2F92EE;'>#白介素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71621, encryptionId=6ca1e1621c4, topicName=白介素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e95336, createdName=budeshao, createdTime=Fri Oct 11 07:15:00 CST 2013, time=2013-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426558, encodeId=390c142655881, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Fri Oct 11 07:15:00 CST 2013, time=2013-10-11, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1953252, encodeId=c30b1953252ab, content=<a href='/topic/show?id=500be1632c1' target=_blank style='color:#2F92EE;'>#白介素-2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71632, encryptionId=500be1632c1, topicName=白介素-2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e12358, createdName=lhlxtx, createdTime=Sat May 24 05:15:00 CST 2014, time=2014-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890796, encodeId=8d781890e9650, content=<a href='/topic/show?id=742341e1782' target=_blank style='color:#2F92EE;'>#基因型#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41717, encryptionId=742341e1782, topicName=基因型)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f984116, createdName=kzlchina, createdTime=Wed Jun 04 03:15:00 CST 2014, time=2014-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1670527, encodeId=53e016e05277d, content=<a href='/topic/show?id=7bc54e43473' target=_blank style='color:#2F92EE;'>#尿毒症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47434, encryptionId=7bc54e43473, topicName=尿毒症患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b24f26728715, createdName=chenwq17, createdTime=Sun Jan 19 08:15:00 CST 2014, time=2014-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257571, encodeId=15d3125e57123, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Fri Oct 11 07:15:00 CST 2013, time=2013-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290387, encodeId=88e6129038e13, content=<a href='/topic/show?id=facb4e432e4' target=_blank style='color:#2F92EE;'>#尿毒症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47432, encryptionId=facb4e432e4, topicName=尿毒症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=74c2229, createdName=tcm99hq, createdTime=Fri Oct 11 07:15:00 CST 2013, time=2013-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338656, encodeId=f6f11338656bf, content=<a href='/topic/show?id=e803851e58' target=_blank style='color:#2F92EE;'>#HBsAg#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8517, encryptionId=e803851e58, topicName=HBsAg)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a5c2500147, createdName=12498bb3m90(暂无昵称), createdTime=Fri Oct 11 07:15:00 CST 2013, time=2013-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372095, encodeId=1e2213e2095f5, content=<a href='/topic/show?id=6ca1e1621c4' target=_blank style='color:#2F92EE;'>#白介素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71621, encryptionId=6ca1e1621c4, topicName=白介素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e95336, createdName=budeshao, createdTime=Fri Oct 11 07:15:00 CST 2013, time=2013-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426558, encodeId=390c142655881, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Fri Oct 11 07:15:00 CST 2013, time=2013-10-11, status=1, ipAttribution=)]
    2013-10-11 gwc384

相关资讯

Journal of Hepatology:基因型特异性HBsAg动力学可指导HBeAg(-)慢性乙肝患者的治疗

在许多地区,乙型肝炎e抗原(HBeAg)阴性(HBeAg(-))慢性乙型肝炎(CHB)是最常见的CHB类型。在过去十余年中,HBeAg(-) CHB的患病率日益增加。基于上述情况,来自意大利比萨大学医院的Maurizia Rossana Brunetto及其同事展开一项研究,研究结果在线发表于2013年7月22日的《肝脏病学杂志》(Journal of&nb

EASL 2013:HBsAg临床应用的研究新进展

       本届欧洲肝脏研究学会(EASL)年会介绍了乙肝表面抗原(HBsAg)临床意义的研究进展,提示HBsAg作为HBV DNA的补充,在预测慢性HBV感染自然转归、抗病毒疗效、停药复发中有重要作用。但当前的研究大多样本量不足、随访时间偏短,将来仍需要更多的研究阐释HBsAg的临床价值。     &n

高嘉宏教授:慢性乙型肝炎(CHB)的管理

作者:台湾大学医院 高嘉宏教授        慢性乙型肝炎(CHB)感染是一个全球健康问题,HBsAg为最早用于临床诊断HBV感染的可靠标志物。近年来,有关HBsAg水平在CHB治疗中的预测价值和指导作用的认识日益加深。       “最大限度地长期抑制HBV,减轻肝细胞炎症坏死及肝纤维化,延缓和阻止疾病进展,减少和

乙肝表面抗原(HBsAg)持续阳性和清除HBsAg策略探讨

    日前,在以“乙肝表面抗原持续阳性的防治策略”为主题的第189期东方科技论坛上,中国工程院院士闻玉梅、庄辉和来自国内外的40余位专家学者就慢性乙型肝炎的防治策略展开了研讨。专家呼吁,应加强多学科的合作研究,重视基础和临床的紧密结合,进一步阐明乙肝表面抗原(HBsAg)持续阳性的机制和清除HBsAg的策略,提升乙肝领域转化型研究的整体水平。   闻玉梅在题为《